The Lariago Tablets from Ipca Laboratories Ltd - long-time malaria workhorse in India

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 03:22. Details in the imprint.

The Lariago Tablets sit in a small white blister strip on the counter, bright logo on the foil, while the pharmacist explains the dosing with a ballpoint tapping on the leaflet. For many Indian families they are a familiar, almost routine companion during malaria season. The tablets feel solid in the hand, chalky and slightly bitter when taken with a glass of water.

Where Lariago fits in

Lariago Tablets from Ipca Laboratories Ltd are a chloroquine-based formulation used for the treatment and prophylaxis of malaria in regions where the parasite remains sensitive to this older molecule. The brand has been present in the Indian market for years and is widely stocked by neighborhood chemists. It addresses both acute attacks and short-term prevention for travelers and residents in endemic districts.

Unlike newer artemisinin-based combinations, Lariago relies on a single well-known active ingredient that many doctors in smaller clinics still prescribe because they know its profile and side effects from long experience. Patients often recognize the name more quickly than the generic, which makes counseling at the counter smoother. The compact blister pack slips easily into a shirt pocket or a small purse on the way home.

Dosage, pack sizes and handling

In practice Lariago Tablets are typically supplied in strengths around 250 mg chloroquine base per tablet, with dosing regimens adjusted to body weight and clinical guidance. Courses usually span several days, starting with a loading dose on day one followed by smaller amounts, so the leaflet becomes an important companion for correct use. Chemists often mark the schedule directly on the outer carton with a felt-tip pen.

Ipca Laboratories has historically offered Lariago in multiple pack sizes so prescribers can choose between short courses for acute episodes and slightly larger cartons for prophylaxis during high-risk weeks. That flexibility matters for cost-sensitive patients, as they avoid paying for tablets they will not use. The foil backing on the blisters tears cleanly, with a dry snap as each tablet is pressed out.

How doctors still use it

For many practitioners in semi-urban and rural India, especially older physicians trained when chloroquine was the frontline standard, Lariago remains part of their mental toolkit. Dr. Rajesh Mehta, a general practitioner in Nagpur, might reach for it when he sees a classic fever pattern in a patient from an area where resistance rates are still low. He pairs it with clear advice about warning signs and follow-up visits.

In these settings practicality often beats novelty. Newer therapies can be more expensive or less consistently available in village outlets, while Lariago’s brand is entrenched in local supply chains. Patients may have seen the same carton in the homes of relatives, which tends to reduce hesitation when the prescription pad comes out. The familiar foil and printed logo provide a quiet sense of continuity in otherwise stressful circumstances.

Strengths and limitations

Lariago’s main strength lies in its simplicity and long track record. The active ingredient chloroquine has been studied for decades, so its safety profile and common side effects are well-documented and taught in medical school curricula across India. That helps doctors counsel patients on nausea, visual disturbances or rare reactions without needing to consult new literature every time.

The flip side is well known: in many parts of the world Plasmodium falciparum has developed significant resistance to chloroquine, which sharply limits Lariago’s role. Where resistance rates are high, guidelines push prescribers towards artemisinin-based combination therapy instead. For investors and public-health observers this tension between familiarity and changing science is central to how legacy brands like Lariago are viewed.

Everyday user experience

From the patient’s perspective the experience is straightforward. The tablets are small enough to swallow with a modest sip of water, and the blister design means they can be taken one by one without exposing the whole strip. The taste is distinctly bitter if the tablet lingers on the tongue, which encourages quick swallowing rather than chewing.

Families often store an unfinished strip in a cool metal tin or a bedside drawer during treatment days, alongside thermometers and paracetamol. When fever spikes at night, the rustle of the blister pack in the dark and the clink of the glass on the steel tray become part of the soundscape of home care. In that sense Lariago is woven into very personal routines, beyond its chemical formula and dosing tables.

Regulation and competition

Ipca Laboratories operates under Indian regulatory frameworks that have gradually tightened on quality and pharmacovigilance, which also affects legacy brands like Lariago. Batch testing, stability data and post-marketing surveillance are part of the backdrop for continued market presence. For a long-standing anti-malarial, maintaining compliance is as important as updating packaging or leaflets.

On the competitive front, other local and multinational firms offer their own chloroquine or combination therapies, including generics that may undercut branded pricing. In tender-driven public procurement, price and supply reliability often determine which labels arrive at government clinics. Lariago’s brand recognition can be helpful in private practice, but it competes directly on cost in institutional settings.

Context and share reference

All told, Lariago Tablets show how Ipca Laboratories Ltd balances long-established brands with newer formulations in its anti-infective portfolio. The company is listed in India, and Ipca Laboratories Ltd shares (ISIN INE571A01038) trade on domestic exchanges with investors watching how mature products like Lariago support overall revenue alongside newer launches.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | INE571A01038 | IPCA LABS | boerse | 69656393 | bgmi